CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 352 enrolled
Drug / intervention
Botulinum purified neurotoxin, Type Abiological
Likely dose
Botulinum purified neurotoxin, Type A 0.1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02184988
NCT02184988Phase 2Completed
CompareCT.gov

A Multi-center, Open Label, Multiple Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines.

Evolus, Inc.·interventional·Posted Jul 9, 2014·Updated Apr 24, 2019

In Brief

A Phase 2 clinical trial evaluating Botulinum purified neurotoxin, Type A for Glabellar Frown Lines. Completed, enrolled 352 participants across 1 site.

Detailed Summary

The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 9, 2014
Enrollment StartAug 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.0 years ago

Interventions

Botulinum purified neurotoxin, Type Abiological

The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.